IL19 and Eczematoid dermatitis: Circulating IL-19 measured in these patients at baseline and during 16 weeks of QD treatment with placebo, 2 mg, or 4 mg of baricitinib was correlated (Spearman’s r = 0.59, p < 0.0001) with the eczema activity and severity index (EASI) (Fig. 8b).